Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.
Ari PelcovitsJozal MooreBrianna BakowRabin NiroulaPamela EganJohn L ReaganPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
Our experience with HMAs and venetoclax showed that outpatient ramp up of venetoclax is safe with a very low risk of laboratory TLS (2.5%) and no evidence of clinical TLS within our cohort.